Stockalyze
Example report. Sign up to run the same analysis on any ticker.
SLS logoSLSEquity research

Report date: 2026-11-18

$13.74-1.12 (-7.54%)Live · delayed quote, informational only

Analysis focus

Provide a balanced, comprehensive analysis: fundamentals and valuation, the Wall Street view, technical posture, and the key forward risks and catalysts.

Summary

SELLAS (SLS) is a pre-revenue biotech whose valuation was reset by one binary event. On November 17, 2026 the stock closed at $19.15, up 156.36% in one session from about $7.47. The move followed the company's announcement of positive topline Phase 3 REGAL data for galinpepimut-S (GPS) in AML, which it described as a statistically significant and clinically meaningful improvement in overall survival [9]. The readout came after a volatile run-up. Shares fell 14.71% to $10.38 on October 28, when the trial reached its 80th event, the trigger for the final analysis [1][14]. That event came about 10 months later than planned, which TIKR said could reflect either a GPS benefit or a stronger-than-assumed control arm [8]. The stock then drifted to $8.55–$9.14 in early November and to $7.47 by November 16 [1][14]. Fundamentals are thin. There was no Q3 2026 revenue. The net loss was $10.1M ($0.05/share), versus $6.8M a year earlier. R&D rose to $7.0M from $4.2M, partly on BLA preparation, and G&A rose to $4.3M from $2.9M, mainly from non-cash stock-based compensation. The release identifies no one-time items to normalize [3][7][13]. The balance sheet is clean but small relative to the valuation: $134.7M of cash, no debt and about $9.3M of liabilities at September 30 [4]. At about $3.90B of market cap and about $3.77B of enterprise value [22], P/E and EV/EBITDA are not meaningful. Price-to-book is roughly 30x [15]. Market cap sits far above the company's own 5-year history, which ranges from $34.0M at end-2023 to $537.0M at end-2025 [16]. No peer multiples were verified, so no peer comparison is made [16][21]. The constructive case starts with the trial result itself: a statistically significant overall-survival result in a pivotal trial, as the company describes it [9]. An FDA filing is targeted for 1H 2027, and a second asset, SLS009 (tambiciclib), adds further catalysts. Its newly diagnosed AML Phase 2 data are due in Q4 2026 and relapsed/refractory data will be presented at ASH on December 12–15, 2026. Earlier SLS009 data showed a 54% response rate in monocytic AML and 57% in TP53-mutated AML [8][21]. Sell-side targets are mostly above the current price. Maxim raised its target to $40 from $30 on November 17 and kept its Buy rating [18]. Finviz shows 4 Buy ratings and a $37.50 average target [21]. The pre-readout Maxim/Alliance average of $32.50 was about 70% above the $19.15 close [17]. The cautionary case starts with dilution and how extended the stock is. A proposed $150.0M public offering, announced at 4:01 PM ET on November 17, pushed shares to about $17.07–$17.10 after hours, down about 10.7% [10][22]. That comes on top of 33% share-count growth year to date, to 203.5M shares [7]. TIKR had warned that a win could require equity funding for a BLA and launch [8]. On technicals, RSI(14) is about 76.6–76.7, overbought [2]. The stock trades about 74% above its 50-day average (~$11.01) and about 116% above its 200-day average (~$8.88) [11]. Returns are about +1,258% over 12 months and about +408% year to date [20]. Short interest is 28.34% of float [21]. Derived levels, not published studies, put resistance near the new $24.89 52-week high. Possible support sits at the prior $15.88 high, then ~$11.01, then ~$7.47 [12]. Analyst coverage is thin and comes only from small-cap brokers. No major bank coverage was found [19]. Aggregator consensus figures conflict, ranging from a stale $6.50 to $40 [6][23][24]. Forward risks include the full data details, the FDA review, how the offering is priced, commercialization costs and the SLS009 readouts [8][10][21].

Findings (24)

On October 28, 2026, SLS fell 14.7% to 18% to close at $10.38 after SELLAS said its Phase 3 REGAL trial of galinpepimut-S in AML had reached the 80th event that triggers the final analysis. By the Nov 16 close the stock was $7.47, about 28% below $10.38 and well below its 52-week high of $15.88 (52-week low $1.39).

High confidence

RTTNews (Oct 29, 2026) gives the $10.38 close, the 14.71% decline and the $1.39 to $15.88 52-week range. TIKR describes an 18% drop after a 223% gain year to date. TipRanks gives the $7.47 Nov 16 close. The 28% figure is calculated from these two prices.

RSI(14) on SLS was about 76.6–76.7 after the November 17, 2026 session, above the conventional 70 overbought threshold, compared with a neutral ~58 in mid-2026.

High confidence

Finviz reports RSI(14) of 76.59 and Tradestie reports 76.668, which it labels overbought. Earlier snapshots in the search results (Tradestie, July 17, 2026; SwingTradeBot) showed RSI near 58.

SELLAS reported no revenue for Q3 2026 and a net loss of $10.1M, or $(0.05) per share, compared with a loss of $6.8M, or $(0.06) per share, in Q3 2025. Trailing P/E, forward P/E and EV/EBITDA are therefore not meaningful, and the company pays no dividend.

High confidence

The company's 8-K Exhibit 99.1 (a primary source) shows no revenue line and gives the net loss and EPS figures above. The release identifies no one-time items. Loss per share fell even though the dollar loss grew, because the share count rose to about 202.4M weighted-average shares, which reflects dilution.

At September 30, 2026, SELLAS held about $134.7M in cash and equivalents, down from $138.3M at June 30. It reported no borrowings, total liabilities of about $9.3M, and 203,527,833 shares outstanding.

High confidence

The 8-K balance sheet shows these cash and liability figures and no debt. Cash fell only about $3.6M against a $10.1M net loss, which suggests non-cash charges and/or equity inflows offset part of the cash burn. Free cash flow is negative, and the company gave no explicit cash runway guidance.

The Phase 3 REGAL trial of galinpepimut-S in AML reached its 80th event in October 2026, which triggers the final analysis. In its Q3 release, the company said it expected to announce topline primary endpoint results in November 2026; this binary event dominates the stock's risk.

High confidence

The 8-K states the 80th event occurred in October 2026 and gives the November topline guidance. TIKR (secondary) reported that shares fell 18% on the day the final-analysis trigger was announced, which shows how volatile the stock is around trial news. No topline results were found in these sources.

Aggregators disagree widely on SLS consensus: TipRanks shows a $40 average (1 analyst), TIKR shows a $32.50 mean target that rose from $6.83 over the year, and Benzinga's page shows a $6.50 average from 2 Buy-rated analysts with a $3 to $10 range. The Benzinga figures appear stale.

Medium confidence

TIKR's Oct 28, 2026 article cites a mean target that went from $6.83 to $32.50, and Stocktwits/Asianet on Mar 4, 2026 cited a $6.83 Koyfin consensus with a 1 Buy / 2 Hold split. Benzinga's figures come from a search snippet; its most recent recorded action is Maxim's move from $7 to $10 on Mar 12, 2026. A median target can't be computed reliably because the pool of covering analysts is so small and inconsistent.

SELLAS's Q3 2026 release (Nov 12, 2026) reports $134.7M of cash, a Q3 net loss of $10.1M ($0.05/share) versus $6.8M a year earlier, R&D of $7.0M versus $4.2M, and 203.5M shares outstanding, up from 153.1M at end-2025. At $7.47 that implies a market cap of roughly $1.5B, with no revenue.

High confidence

All financial figures come from the company's primary press release; the market cap is calculated as 203.5M shares times the $7.47 TipRanks close. Shares outstanding grew about 33% year to date, showing equity dilution. The release has no one-time items to normalize, but it attributes the higher G&A ($4.3M vs. $2.9M) mainly to non-cash stock-based compensation.

Analyst targets depend on a binary near-term catalyst. SELLAS said the REGAL 80th event came in October 2026, about 10 months later than planned according to TIKR, and that topline overall-survival results are expected in November 2026. SLS009 (tambiciclib) newly diagnosed AML Phase 2 data are due in Q4 2026, and relapsed/refractory AML data will be presented at ASH on December 12 to 15, 2026.

High confidence

The company release gives the timing of the 80th event and the topline results, the SLS009 enrollment (40 of 80) and the ASH dates. TIKR notes the 10-month delay and argues it could reflect either a benefit from GPS or a stronger-than-assumed control arm, and that a win could require equity funding for a BLA and launch. No topline REGAL result was found as of Nov 18, 2026.

SLS closed at $19.15 on November 17, 2026, up $11.68 (+156.36%) in one session from a prior close of about $7.47, after SELLAS announced positive topline data from the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in AML, which it described as a statistically significant and clinically meaningful improvement in overall survival.

High confidence

Finviz shows the Nov 17 close of $19.15 (+11.68, +156.36%) next to a same-day GlobeNewswire headline on positive REGAL data and a Stocktwits headline reporting a 41% reduction in risk of death. Tradestie, updated Nov 17, 2026, also shows $19.15 (+156.36%). I could not open the full press release, so the hazard ratio, p-value and median OS are not independently checked here.

The rally was partly reversed after hours on November 17, 2026: SLS traded at $17.10 (-10.70%) after SELLAS announced a proposed $150.0 million underwritten public offering at 4:01 PM ET, which dilutes holders of roughly 203.5 million existing shares.

High confidence

Finviz lists the after-hours price of $17.10 (-10.70%) and a 5:17 PM headline that the stock fell on the $150M offering. The company's Q3 2026 release reports 203,527,833 common shares outstanding as of Sept 30, 2026.

As of the November 17, 2026 close, SLS traded about 74% above its 50-day simple moving average (~$11.01) and about 116% above its 200-day simple moving average (~$8.88), an extended uptrend.

High confidence

Finviz shows SMA50 +73.98% and SMA200 +115.73%. Tradestie independently lists the 50-day at $11.01 and the 200-day at $8.88, which matches $19.15 divided by 1.74 and 2.16.

Key technical levels: resistance at the new 52-week high of about $24.89 set around the Nov 17 spike, then the prior high of $15.88 (June 30, 2026), now the first possible support, followed by the ~$11.01 50-day average and the ~$7.47 pre-data close.

Medium confidence

Tradestie now shows a 52-week range of $1.39–$24.89. Finviz still shows a $15.88 high, which looks not yet updated. SwingTradeBot and RTTNews date the $15.88 high to June 30, 2026. These levels are derived from reported prices and averages, not published support and resistance studies.

Q3 2026 operating expenses rose to about $11.3M: R&D was $7.0M (up from $4.2M) and G&A was $4.3M (up from $2.9M). The nine-month net loss reached $28.1M, compared with $19.2M a year earlier.

High confidence

The 8-K attributes the R&D increase to manufacturing, consulting and clinical costs to prepare a possible Biologics License Application (BLA) for galinpepimut-S (GPS). It attributes the G&A increase partly to non-cash stock-based compensation and professional fees, which are recurring costs rather than one-time items.

Before the data, SLS was volatile: it fell 14.71% to $10.38 on October 28, 2026, the day SELLAS said REGAL had reached its 80th overall survival event that triggers the final analysis, then traded around $8.55–$9.14 in early November (close of $8.58 on November 9).

Medium confidence

RTTNews (Oct 29, 2026) reports the $10.38 close, down 14.71%, alongside the 80th-event announcement. Stocktwits coverage reported moves to $8.55 and $9.14 in early November, and Benzinga shows a Nov 9 close of $8.58. Prices differ slightly across aggregators.

Using about $126M of book equity (about $135M of cash less $9.3M of liabilities), the $3.90B market cap implies a price-to-book ratio of roughly 30x. The valuation rests almost entirely on the outcome of the Phase 3 REGAL trial rather than on tangible assets.

Medium confidence

This P/B is an analyst calculation from the 8-K balance sheet and the aggregator's market cap, not a reported metric. It is an approximation and moves with the volatile share price.

SLS's market cap has risen from about $34.0M at end-2023 and $73.2M at end-2024 to $537.0M at end-2025 and about $3.90B in November 2026. That puts current valuation far above anything in its own 5-year history, including $87.8M at end-2021.

Medium confidence

Stockanalysis.com's year-end market cap table (secondary) shows this progression. Trefis lists $2.9B at 6/30/2026. Because earnings-based multiples have been negative throughout, market cap and P/B are the only usable historical yardsticks. No peer multiples were verified in this research pass, so no peer comparison is made.

Sell-side coverage is thin and dates from before the readout. Maxim reaffirmed a $30 target on August 19, 2026, and Alliance Global Partners raised its target to $35 from $25 on August 17, 2026, for an average of $32.50, about 70% above the $19.15 close on Nov 17.

Medium confidence

Stocktwits news (secondary) reports both analyst actions and cites Koyfin's $32.50 average target. With only two analysts, and targets set before the REGAL data, these figures may change sharply once topline results are released.

On November 17, 2026, Maxim Group analyst Jason McCarthy kept a Buy rating on SLS and raised his price target from $30 to $40, about 5.4 times the $7.47 Nov 16 close. This is the only target change within the last 90 days that a source names, and the firm and analyst behind it.

Medium confidence

TipRanks lists Maxim/McCarthy as 'Buy (reiterated), $30 → $40, 11/17/26'. Search coverage of Stocktwits separately mentions Maxim reiterating Buy with a $30 target earlier, before the raise.

No source found any rating or price target on SLS from Goldman Sachs, Morgan Stanley, JPMorgan, BofA, Citi, Wells Fargo or Barclays. Sell-side coverage comes from small-cap brokers, namely Maxim Group and Alliance Global Partners, so a comparison of each major bank's target to the current price cannot be made.

Medium confidence

TipRanks names only Maxim Group and Alliance Global Partners as covering analysts. The Stocktwits headline 'JPMorgan Buys In And Stifel Boosts Bet' appears to describe institutional position changes, not analyst ratings. That article returned HTTP 403, so its content could not be checked directly.

SLS returned about +152% over 6 months, about +1,258% over 12 months and about +408% year-to-date through November 17, 2026, against a 52-week low of $1.39.

Medium confidence

Finviz lists Perf Half Y +152.31%, Perf Year +1258.16% and Perf YTD +407.96%. RTTNews confirms the $1.39 52-week low. Confidence is medium because aggregator return windows can lag a 156% single-day move.

At a market cap of about $3.90B, SELLAS has no product revenue. It held $134.7M in cash at September 30, 2026 and reported a Q3 2026 net loss of $10.1M ($0.05/share), so the valuation rests mainly on future GPS approval and commercialization (FDA filing targeted for 1H 2027) and on SLS009 (tambiciclib), not on current earnings.

Medium confidence

The company's Q3 2026 release (primary) gives cash of $134.7M, net loss of $10.1M, R&D of $7.0M and SLS009 Phase 2 ASH data (54% ORR in monocytic AML, 57% ORR in TP53-mutated AML). Finviz gives the $3.90B market cap and a headline on a 1H 2027 FDA filing. Sell-side views per Finviz: 4 Buy ratings, average target $37.50, short float 28.34%. These are aggregator figures, and no peer or 5-year multiple comparison is meaningful for a pre-revenue biotech.

SELLAS Life Sciences (SLS) closed at $19.15 on November 17, 2026, which gives a market capitalization of about $3.90 billion and an enterprise value of about $3.77 billion; the after-hours quote that day was lower, at $17.07.

Medium confidence

Stockanalysis.com, a secondary aggregator, lists these figures as of Nov 17, 2026. EV is about market cap minus the roughly $134.7M of cash. Other aggregators showed $2.27B–$2.45B in late October 2026, when the price was about $11.35. The stock has been moving sharply, so the figure depends heavily on the quote date.

As of the November 16, 2026 close of $7.47, TipRanks shows SLS with a 'Moderate Buy' consensus from 1 Buy, 0 Hold and 0 Sell rating in the past 3 months, and a single 12-month price target of $40.00 that is the average, high and low, implying about 435% upside.

Medium confidence

The TipRanks forecast page shows the $7.47 close on Nov 16, a 1/0/0 rating split, and a $40 average, high and low target. That average rests on one analyst only, because TipRanks counts only ratings from the last 3 months. The same page's monthly trend table shows 3 Strong Buys for November, which contradicts its own summary.

Alliance Global Partners analyst James Molloy raised his SLS target from $10 to $25 on July 6, 2026, and a later report says he raised it again from $25 to $35 with a Buy rating. A $35 target would be about 4.7 times the $7.47 Nov 16 close.

Low confidence

TipRanks shows the July 6, 2026 move from $10 to $25 and does not show any later Alliance action. The move from $25 to $35 appears only in search-result summaries of secondary coverage, with no date confirmed, so whether $25 or $35 is the current Alliance target is unverified.

Sources (19)

Caveats

Time-sensitivity is extreme. Several findings ([1], [5], [8], [23]) were written before the November 17 readout and state that no topline result had been found. Findings [9]–[11], [21] and [22] reflect the post-data price, so valuation figures depend heavily on the quote date. Market cap is about $1.5B at $7.47 [7] versus about $3.90B at $19.15 [22]. The REGAL trial details were not independently checked. The hazard ratio, p-value and median OS come only from headlines, including a Stocktwits '41% reduction in risk of death' claim, because the full press release could not be opened [9]. The terms and pricing of the $150M offering were not available [10]. P/B, EV and the dilution estimates are approximate calculations from aggregator data [15][22]. Analyst data is the weakest area. TipRanks, TIKR, Benzinga, Koyfin and Finviz disagree. TipRanks' own summary and its monthly trend table contradict each other. Alliance's current target ($25 vs. $35) is unverified. The Benzinga figures appear stale. No major-bank coverage exists [6][19][23][24]. Most price, technical and consensus data comes from secondary aggregators such as Finviz, Tradestie, TipRanks, Stockanalysis.com and Stocktwits. Only the Q3 financials come from primary SEC and company sources [3][4][7][13]. Finviz's 52-week high and its return windows may lag the one-day move [12][20]. No peer valuation comparison, cash-runway guidance, competitive landscape for AML, institutional ownership analysis, options or implied-volatility data, or post-offering share count is covered. This report is not a buy, sell or hold recommendation.

This report is for informational purposes only and is not investment advice. No buy / sell / hold recommendation is made or implied.

More research reports

Recent reports from the same pipeline. See all examples

Want this on your watchlist?

Add your own focus, pick a delivery speed, and get a source-verified report like this one.